Feasibility of Treatment for Vaping Cessation

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Researchers are gathering information on the feasibility of treating e-cigarette users with 12-weeks of varenicline (Chantix®) in assisting with stopping the use of e-cigarettes.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Varenicline

Criteria

Inclusion Criteria:

• ≥18 years and ≤65 years of age;

• No use of tobacco in any form (except E-cigarettes) in the past 3 months;

• currently using e-cigarettes

Exclusion Criteria:

• Current moderate or severe depression

• Use of any treatments for tobacco dependence within the past 30 days;

• Recent history (past 3 months) of abuse of, or dependence on, a substance other than nicotine;

• Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase, or a male who is able to father a child, and are not willing to use a reliable form of contraception,

• Subject describes having a medical history of: a) unstable angina; b) myocardial infarction within the past 3 months; c) coronary angioplasty; or d) an untreated cardiac dysrhythmia;

• Subject currently has cancer [excluding non-melanoma skin cancer] not in remission;

• Known allergy to varenicline;

• Subject has a medical condition deemed by the investigators to be exclusionary to the study.